This company listing is no longer active
Oncoinvent Management
Management criteria checks 1/4
Oncoinvent's CEO is Oystein Soug, appointed in Sep 2024, has a tenure of 1.08 years. total yearly compensation is NOK2.79M, comprised of 32.9% salary and 67.1% bonuses, including company stock and options. directly owns 0.15% of the company’s shares, worth NOK199.50K. The average tenure of the management team and the board of directors is 1.2 years and 1.5 years respectively.
Key information
Oystein Soug
Chief executive officer
NOK 2.8m
Total compensation
| CEO salary percentage | 32.89% |
| CEO tenure | 1.1yrs |
| CEO ownership | 0.2% |
| Management average tenure | 1.2yrs |
| Board average tenure | 1.5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | -NOK 107m |
| Mar 31 2025 | n/a | n/a | -NOK 123m |
| Dec 31 2024 | NOK 3m | NOK 916k | -NOK 140m |
Compensation vs Market: Oystein's total compensation ($USD276.78K) is about average for companies of similar size in the Norwegian market ($USD355.44K).
Compensation vs Earnings: Insufficient data to compare Oystein's compensation with company performance.
CEO
Oystein Soug (56 yo)
Mr. Oystein Soug, M.Sc, serves as Chief Executive Director of Oncoinvent AS since September 01, 2024. Mr. Soug was Chief Executive Director of Arxx Therapeutics. He served as an Interim Chief Financial Off...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 1.1yrs | NOK 2.79m | 0.15% NOK 199.5k | |
| Chief Financial Officer | no data | NOK 1.86m | no data | |
| Chief Operating Officer | 1.2yrs | NOK 2.03m | no data | |
| Chief Production Officer | no data | NOK 1.56m | no data | |
| Head of Regulatory Affairs | 4yrs | NOK 1.45m | no data | |
| Chief Medical Officer | 4yrs | NOK 2.17m | no data | |
| Head of Quality Assurance & Employee Representative Director | no data | NOK 1.39m | 0.013% NOK 17.5k | |
| Chief Clinical Officer | 1.2yrs | NOK 1.98m | no data | |
| Head of Health Safety & Environment | 1.2yrs | no data | no data | |
| Head of Quality Control | less than a year | no data | no data |
Experienced Management: ONCOI's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Head of Quality Assurance & Employee Representative Director | no data | NOK 1.39m | 0.013% NOK 17.5k | |
| Chairman of Scientific & Clinical Advisory Board | 1.5yrs | NOK 367.00k | no data | |
| Member of Scientific Clinical Advisory Board | no data | NOK 298.00k | no data | |
| Director | 1.5yrs | no data | no data | |
| Chair of the Board | 1.5yrs | no data | 0.36% NOK 465.5k | |
| Director | less than a year | no data | no data | |
| Director | 1.5yrs | no data | 0.25% NOK 328.6k | |
| Director | 1.5yrs | no data | 0.077% NOK 99.7k | |
| Director | 1.5yrs | no data | no data | |
| Board Observer | no data | no data | no data |
Experienced Board: ONCOI's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/31 21:55 |
| End of Day Share Price | 2025/10/29 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Oncoinvent ASA is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Geir Holom | DNB Carnegie |